URGN: UroGen Pharma Revenue and Sales Volume

Corporate emblem and logo of urogen.com (URGN)

UroGen Pharma Ltd. (URGN) is implementing automation in the production of sterile hydrogels, complementing this with the digitalization of clinical trial reporting. The company's sales dynamics demonstrate a long-term trend, where the current metric remains around 0.25. Management is effectively commercializing innovative therapies for bladder cancer, consistently expanding the medical evidence base for its drugs.

UroGen Pharma (URGN) - Company Revenue from 07/04/2022 to 11/17/2026

Comprehensive metric breakdowns and analytics for urogen.com (URGN)

- market price and analyst price targets:
- market capitalization information:
Comprehensive company analysis:UroGen Pharma URGN
Mass-produced product of UroGen Pharma Ltd.

Steady revenue growth confirms the long-term sustainability of UroGen Pharma Ltd. (URGN) for strategic capital. This indicator captures actual cash flow from sales, excluding accounting estimates. An analysis of corporate sales allows for an assessment of business scaling rates and the precision of market positioning. This price action reflects the expansion of innovative gel-based drugs within specialized clinics. The growth of the professional center network converts directly into an upward trend for this metric.

Competing companies

Company Revenue ONC|Revenue and Sales Volume HALO|RVMD (Revolution Medicines, Inc.) - Company Sales Revenue|Company Revenue Ascentage Pharma Corp AAPG|Company Total Sales Volume CG Oncology, Inc.|bicara.com - Revenue and Sales Volume|Company Sales Revenue PSNL (personalis.com)|Erasca Inc (ERAS) - Company Revenue|Company Sales Delcath Systems|YMAB (YmAbs) - Revenue and Sales Volume|AURA: Company Sales Revenue|Company Revenue Candel Therapeutics, Inc. (CADL)|Revenue and Sales Volume Accuray (ARAY)|Company Revenue SELLAS Life Sciences Group Inc. SLS|Actuate Therapeutics, Inc (ACTU) - Company Total Revenue|CTOR - Company Revenue|HURA: Company Revenue|TARA (Protara) - Company Sales|Fate Therapeutics, Inc. - Company Sales Revenue|WHWK (aadibio.com) - Revenue and Sales Volume|TCRX: Company Sales Revenue|Company Revenue Champions Oncology (CSBR)|XBiotech - Company Sales Volume|Company Revenue CEL-SCI CVM|Company Gross Revenue OS Therapies (OSTX)|Radiopharm Theranostics Limited - Revenue and Sales Volume|Company Total Revenue Artiva Biotherapeutics|ANL (adlainortye.com) - Company Sales|Company Sales Veru Pharma|TPST (Tempest Therapeutics Inc) - Revenue and Sales Volume|Xilio Therapeutics, Inc. (XLO) - Company Gross Revenue|Company Revenue Enochian BioSciences (RENB)|MURA: Company Annual Revenue|Revenue and Sales Volume KAPA (kairospharma.com)|Company Gross Revenue OnKure (OKUR)|CytoMed Therapeutics Ltd - Revenue and Sales Volume|curis.com (CRIS) - Company Sales|Apollomics Corp (APLM) - Company Revenue|Tharimmune - Company Sales Revenue|ADVB (Advanced Biomed Corp) - Revenue and Sales Volume|Company Sales Genprex, Inc (GNPX)|Revenue and Sales Volume CLDI|SBFM: Company Annual Revenue|Revenue and Sales Volume XBIO (xeneticbio.com)|Revenue and Sales Volume Salarius Pharmaceuticals Inc SLRX|purple-biotech.com - Revenue and Sales Volume|Company Total Revenue American Oncology Network, Inc.|BGNE: Revenue and Sales Volume|Company Sales checkpointtx.com|Company Revenue Elevation Oncology, Inc.|iCAD, Inc. (ICAD) - Company Gross Revenue|Company Revenue Ikena (IKNA)|NTBL - Company Total Revenue|Company Revenue viracta.com VIRX|morphosys.com (MOR) - Company Total Revenue|NAYA Biosciences Inc - Revenue and Sales Volume|AAPGV: Company Revenue